Since several clinically approved drugs for the treatment of cancer target various protein tyrosine kinases including Bcr-Abl and Src [14], we hypothesized that one or more of these compounds might also inhibit the SIKs in vivo, thereby opening the possibility of repurposing these therapeutics for the treatment of chronic inflammatory diseases. This evidence concerns the gene SRC and cancer.